Document:

<PAGE>

                                                                    EXHIBIT 10.8

                                   AGREEMENT

                         (THE "REQUIREMENT AMENDMENT")

between

GARCHING INNOVATION GMBH MUNICH, GERMANY

                                                                          ("GI")

and

ALNYLAM PHARMACEUTICALS, INC., CAMBRIDGE, USA (FORMERLY KNOWN AS ALNYLAM HOLDING
CO., INC.)

                                                              ("Alnylam Pharma")

and

ALNYLAM US, INC., CAMBRIDGE, USA (FORMERLY KNOWN AS ALNYLAM PHARMACEUTICALS,
INC.)

                                                                  ("Alnylam US")

and

ALNYLAM EUROPE AG, KULMBACH, GERMANY (FORMERLY KNOWN AS RIBOPHARMA AG)

                                                             ("Alnylam Germany")

(GI, Alnylam Pharma, Alnylam US and Alnylam Germany are hereinafter referred to
as the "Parties")

<PAGE>

                                      - 2

PREAMBLE

WHEREAS, Alnylam US and GI are parties to the Alnylam Co-Exclusive License
Agreement dated as of December 20, 2002 (the "Alnylam License Agreement"),
pursuant to which Alnylam US received one of two proposed co-exclusive licenses
from GI to the patents described therein;

WHEREAS, Max Planck Gesellschaft zur Foerderung der Wissenschaften e.V. ("MPG"),
co-owner of the patents licensed under the Alnylam License Agreement (and only
MPG but none of the other co-owners of the licensed patents), established the
requirement to develop and commercialize the licensed patents also in Germany,
due to the fact that Tom Tuschl, a main inventor of the licensed patents, made
his inventions at a Max Planck Institute in Germany in the course of a project
funded by the German government; MPG (and only MPG but none of the other
co-owners of the licensed patents) requested from GI to negotiate and implement
in the respective agreements a Comparability Requirement (as defined below) and
a Split of Indications Requirement (as defined below);

WHEREAS, the Alnylam License Agreement provides for the grant of a second
co-exclusive license to a European-based therapeutics company consisting of,
among other things, a German company that must have comparable operational
forces in terms of budget, employees, R&D and BD capacities as Alnylam US
("Europe RNAi") to be established by Alnylam US;

WHEREAS, Alnylam US and Alnylam Germany entered into a share exchange agreement
dated as of July 3, 2003 (the "Share Exchange Agreement") pursuant to which both
entities became wholly-owned subsidiaries of Alnylam Pharma;

WHEREAS, the equity ownership structure provided for under the Share Exchange
Agreement did not comply with certain of the requirements set forth in Appendix
C of the Alnylam License Agreement;

WHEREAS, under an Amendment to the Alnylam License Agreement dated as of July 2,
2003 (the "Garching Amendment"), GI agreed that Alnylam Germany qualifies as
Europe RNAi as described in the Alnylam License Agreement, provided that, among
other terms and conditions set forth in the Garching Amendment, for a period of
5 years after the effective date as defined in the Alnylam License Agreement (i)
Alnylam Pharma is required to use reasonable commercial efforts to build for
Alnylam Germany capabilities to develop, make, use, sell or import license
products comparable to Alnylam US and (ii) Alnylam Germany must have comparable
operational forces in Germany in terms of budget, employees, research and
development and business development capabilities as Alnylam US (conditions (i)
and (ii) above are hereinafter jointly referred to as the "Comparability
Requirement");

Requirement Amendment
Execution Copy

<PAGE>

                                     - 3 -

WHEREAS, GI and Alnylam Germany are parties to a Ribopharma Co-Exclusive License
Agreement dated as of July 30, 2003 (the "Ribopharma License Agreement")
pursuant to which GI granted a second co-exclusive license to Alnylam Germany
(formerly known as Ribopharma AG);

WHEREAS, under Section 2.3 of each the Alnylam License Agreement and the
Ribopharma License Agreement, Alnylam US, Alnylam Germany and GI have undertaken
to mutually agree on a reasonable and equal split of indications and
sub-indications according to the estimated market size and accessibility by RNAi
within the field between Alnylam US and Alnylam Germany (hereinafter referred to
as the "Split of Indications Requirement");

WHEREAS, Alnylam US and Alnylam Germany issued to GI a confidential report dated
as of January 10, 2005, pursuant to which Alnylam US and Alnylam Germany
asserted their compliance with the Comparability Requirement and the Split of
Indications Requirement;

WHEREAS, on January 20, 2005 GI issued to Alnylam US and Alnylam Germany a
deficiency notice regarding the Comparability Requirement, according to Section
C) 5.c) of the Garching Amendment (the "Deficiency Notice"), and an
insufficiency notice regarding the Split of Indications Requirement according to
Section 2.3 of the Alnylam License Agreement and Section 2.3 of the Ribopharma
License Agreement (the "Insufficiency Notice"); and

WHEREAS, without prejudice to, and/or acknowledging any default under, any of
the contractual obligations described above, the Parties engaged into further
discussions intended to reach amicable agreement with respect to the matters
cited below and to settle any controversy arising out of the Comparability
Requirement and the Split of Indications Requirement;

NOW THEREFORE, the Parties agree with respect to the foregoing as follows:

1.    Alnylam Pharma, Alnylam US, Alnylam Germany and GI agree that with respect
      to the scope, content, reporting, failure, cure and termination procedure,
      and any other terms and conditions (including without limitation Sections
      A) 1., A) 3. d), and C) 5. a) through c) of the Garching Amendment) in
      connection with the Comparability Requirement set forth in the Alnylam
      License Agreement, the Garching Amendment and the Ribopharma License
      Agreement as well as the requirements set out in Sec. 10.2 of the Share
      Exchange Agreement (collectively, the "Comparability Requirement Terms and
      Conditions"), the Comparability Requirement Terms and Conditions shall be
      amended as follows (the amended Comparability Requirement Terms and
      Conditions set forth in (i) through (vi) below collectively the "Amended
      Comparability Requirement Terms and Conditions"):

Requirement Amendment
Execution Copy

<PAGE>

                                      - 4 -

      (i) For a period until December 20, 2007 (the "Period"), Alnylam Pharma
      (or any successor or assignee of Alnylam Pharma) is obliged to maintain
      Alnylam Germany as an operating company in Germany with at least a number
      of employees collectively equal to 25 full-time equivalent employees
      ("FTEs") (such number may include the management of Alnylam Germany and
      incoming employees who have signed their employment contracts with Alnylam
      Germany but have not yet commenced their employment) having their legal
      and habitual residence in Germany and working at least 75% of their
      working time in Germany, and

      (ii) Alnylam Pharma (or any successor or assignee of Alnylam Pharma) shall
      ensure for the Period that 10 of the 25 FTEs as defined under (i) above
      are scientists with at least a doctoral-level degree, and a further 4 of
      these 25 FTEs are diploma scientists ("Academic Quota"), unless the
      Parties have agreed on a different Academic Quota, it being understood
      that Alnylam Pharma may propose - at any time - adjustments to the
      Academic Quota subject to GI's approval, which approval shall not be
      unreasonably withheld by GI, provided that Alnylam Pharma has given
      sufficient reasons for its proposed adjustments.

      (iii) Alnylam Pharma (or any successor or assignee of Alnylam Pharma)
      shall provide GI, within 30 days after the end of each calendar quarter,
      with calendar quarterly reports (the "Reports") showing in sufficient
      detail how Alnylam Pharma has fulfilled during the immediately preceding
      calendar quarter and intends to fulfil in the calendar quarter in which
      the respective Report is submitted, its obligations set forth in (i) and
      (ii) above; the first Report shall be delivered to GI for the first
      calendar quarter 2005, and

      (iv) In the event GI informs Alnylam Pharma in writing, within 30 (thirty)
      days after receipt of the respective Report, that Alnylam Pharma failed to
      comply with one or more of its obligations set forth in (i) and (ii) above
      (the "Failure Notice"), and Alnylam Pharma fails to cure that breach
      within 90 days after receiving the Failure Notice or, if such breach is
      the result of one or more employees leaving their employment with Alnylam
      Germany, within 180 days after the final date of employment of such
      employee, whichever period is longer ("Grace Period"), GI shall have the
      extraordinary right, but subject to the procedure set forth in clause 1(v)
      below, to terminate the Ribopharma License Agreement in writing with 30
      days prior notice to Alnylam Pharma. In the event of such termination,
      Sections 11.7, 11.8 and 12.3 of the Ribopharma License Agreement shall not
      apply, and such termination of the Ribopharma License Agreement shall be
      GI's sole remedy under any or all of this Requirement Amendment, the
      Ribopharma License Agreement, the Alnylam License Agreement and the
      Garching Amendment for failure by Alnylam Pharma (or any successor or
      Assignee of Alnylam Pharma) to comply with the obligations set forth in
      1(i) and 1(ii) above.

Requirement Amendment
Execution Copy

<PAGE>

                                     - 5 -

      (v) Within 30 days after the end of the Grace Period, Alnylam Pharma may
      provide written notice to GI in sufficient detail to demonstrate that the
      Amended Comparability Requirement Terms and Conditions were fulfilled
      within the Grace Period, or, despite diligent efforts to fulfill them,
      were not fulfilled within the Grace Period for reasons outside the
      reasonable control of Alnylam Pharma, e.g. because it has not been
      possible within such Grace Period to recruit an appropriate individual for
      a vacant position. In the event that, after giving reasonable
      consideration to such written notice from Alnylam, GI does not agree that
      Alnylam Pharma has fulfilled, or used diligent efforts to fulfill, the
      Amended Comparability Requirement Terms and Conditions within the Grace
      Period, GI shall have the right to seek termination of the Ribopharma
      License Agreement by initiating arbitration in accordance with Section
      12.3 of the Ribopharma License Agreement, with the following
      modifications:

            (a)   the only matter on which the arbitrators will be asked to rule
                  is whether Alnylam Pharma has met, or has used diligent
                  efforts to meet, the Amended Comparability Requirement Terms
                  and Conditions;

            (b)   if the arbitrators rule that Alnylam Pharma has met, or has
                  used diligent efforts to meet, the Amended Comparability
                  Requirement Terms and Conditions, GI shall not have the right
                  to terminate the Ribopharma License Agreement and shall bear
                  all costs of the arbitration; and

            (c)   if the arbitrators rule that Alnylam Pharma has not met, or
                  has not used diligent efforts to meet, the Amended
                  Comparability Requirement Terms and Conditions, GI shall have
                  the right to terminate the Ribopharma License Agreement
                  immediately, and Alnylam Pharma shall bear all costs of the
                  arbitration.

      (vi) GI shall herewith waive and Alnylam Pharma, Alnylam US and Alnylam
      Germany shall herewith accept such waiver of any and all rights including
      but not limited to any right of GI to terminate the Alnylam License
      Agreement and/or the Ribopharma License Agreement based on an asserted
      default under the Comparability Requirement Terms and Conditions.

2.    Alnylam Pharma, Alnylam US, Alnylam Germany and GI agree that with respect
      to the Split of Indications Requirement set forth in the Alnylam License
      Agreement and the Ribopharma License Agreement (i) Alnylam US and Alnylam
      Germany shall be fully and irrevocably released from the Split of
      Indications Requirement and all and any pending, threatened or asserted
      claims arising out of any asserted default under the Split of Indications
      Requirement, and (ii) GI shall herewith waive and Alnylam Pharma, Alnylam
      US and Alnylam Germany shall herewith accept such waiver of any and all
      rights including but not limited to any

Requirement Amendment
Execution Copy

<PAGE>

                                     - 6 -

      right of GI to terminate the Alnylam License Agreement and/or the
      Ribopharma License Agreement based on an asserted default under the Split
      of Indications Requirement.

3.    Alnylam Pharma, Alnylam US, Alnylam Germany and GI agree that in each of
      the Alnylam License Agreement and the Ribopharma License Agreement,
      Section 4.2 shall be amended to read as follows:

            "COMPANY shall furnish, and shall oblige its AFFILIATES and
            SUBLICENSEES to furnish to COMPANY for inclusion in its reports to
            GI, to GI in writing, within 30 (thirty) days after the end of each
            calendar year, with COMPANY's standard R&D report, on the progress
            of its efforts during the immediately preceding calendar year to
            develop and commercialize LICENSED PRODUCTS for each indication and
            sub-indication within the FIELD. The report shall also contain a
            discussion of intended R&D efforts for the calendar year in which
            the report is submitted."

4.    Alnylam Pharma, Alnylam US, Alnylam Germany and GI agree that in each of
      the Alnylam License Agreement and the Ribopharma License Agreement, the
      final paragraph of Section 4.3 shall be amended to read as follows:

            "If GI decides that COMPANY did not fulfill the requirements of (a)
            or (b), and/or that COMPANY's terms and conditions for the requested
            sublicense have been unreasonable (in either case, a "Sublicensing
            Deficiency"), GI may provide COMPANY with notice in writing
            ("Sublicensing Deficiency Notice") of such decision. Within thirty
            (30) days of receiving such Sublicensing Deficiency Notice, COMPANY
            shall provide GI within a written reply proposing a plan to correct
            such Sublicensing Deficiency, and/or explaining COMPANY's reasonable
            belief that no such Sublicensing Deficiency exists. If COMPANY does
            not provide a written reply to GI within thirty (30) days after
            receiving such Sublicensing Deficiency Notice, or if after giving
            such reply due consideration, including discussing such reply with
            COMPANY, GI reasonably concludes that such Sublicensing Deficiency
            does exist and/or that COMPANY's proposed corrective plan is
            inadequate, GI may initiate the arbitration procedure according to
            Section 12.3. If the award of the arbitration tribunal states a
            non-fulfillment of the requirements of (a) or (b), COMPANY shall
            immediately start negotiations with the third party; if the award of
            the arbitration tribunal states unreasonable terms and conditions,
            COMPANY shall immediately re-negotiate reasonable terms and
            conditions with the third party. In any such awards of the
            arbitration tribunal, the costs for the arbitration procedure shall
            be borne solely by COMPANY."

Requirement Amendment
Execution Copy

<PAGE>

                                     - 7 -

5.    In consideration for the agreements of GI set out in paragraphs 1 through
      4 above, Alnylam Pharma shall issue and transfer, within 30 days after the
      Amendment Execution Date, a total of 270,000 (two hundred seventy
      thousand) fully-paid shares of Alnylam Pharma Common Stock, such shares to
      be free of any restrictions on transfer other than any restrictions
      required under applicable U.S. securities laws (the "Compensation
      Shares"). The Compensation Shares shall be distributed in accordance with
      written instructions (the "Distribution Instructions") to be provided by
      GI to Alnylam Pharma within 5 days after the Amendment Execution Date,
      instructing Alnylam Pharma to issue and transfer such Compensation Shares
      either

      (i) in total to MPG, in which case it shall be GI's sole and exclusive
      responsibility to split the Compensation Shares and to cause MPG to assign
      and transfer any part of the Compensation Shares to any of the
      Massachusetts Institute of Technology ("MIT") and/or the Whitehead
      Institute ("WI") (MIT, WI and MPG collectively the "Approving Owners" as
      defined in the Ribopharma License Agreement). In such case, however,
      Alnylam Pharma shall diligently assist and support MPG in connection with
      any further assignment and transfer of any portion of the Compensation
      Shares; in particular, Alnylam Pharma shall, and, as necessary or useful,
      shall instruct its respective consultants or agents (e.g., EquiServe
      Trust) to, execute any documents or take any other action required under
      applicable U.S. securities law in order to implement any further
      assignment and transfer of any portion of the Compensation Shares in the
      most expeditious manner;

      or

      (ii) in portions to the Approving Owners in accordance with a share
      distribution scheme set forth by GI in the Distribution Instructions.

      The Distribution Instructions shall also include written confirmation from
      each Approving Owner that it approves this Requirement Amendment.

      MPG (or any of its successors or assignees) and the Approving Owners shall
      be and remain the owner of the Compensation Shares, including without
      limitation in the event that this Requirement Amendment or any of the
      Alnylam License Agreement, the Garching Amendment or the Ribopharma
      License Agreement is terminated.

6.    GI shall represent and warrant that it has the right and authority to
      enter into this Requirement Amendment and that such Requirement Agreement,
      in particular the Amended Comparability Requirement Terms and Conditions
      and the release from the Split of Indications Requirements as agreed in
      this Requirement Amendment, does not conflict with any rights and claims
      of third parties, in particular of the

Requirement Amendment
Execution Copy

<PAGE>

                                     - 8 -

      Approving Owners. GI shall defend, indemnify and hold harmless Alnylam
      Pharma, Alnylam US and Alnylam Germany, as well as its directors and
      officers against any claims of third parties, in particular the Approving
      Owners, irrespective on what basis, against Alnylam Pharma, Alnylam US
      and/or Alnylam Germany because of this Requirement Amendment or any of the
      Amended Comparability Requirement Terms and Conditions or the release from
      the Split of Indications Requirement as agreed in this Requirement
      Amendment.

7.    This Requirement Amendment shall come into effect on June 15, 2005 (the
      "Amendment Execution Date") and shall remain in effect for the term of the
      Alnylam License Agreement and the Ribopharma License Agreement. Until the
      Amendment Execution Date, GI herewith agreed to suspend the Deficiency
      Notice and the Insufficiency Notice.

8.    This Requirement Amendment shall be governed by and construed in
      accordance with the laws of Federal Republic of Germany. Any controversy
      arising out of or in connection with this Requirement Amendment shall be
      subject to arbitration under the procedural Rules of the International
      Chamber of Commerce. The arbitration tribunal shall be appointed as
      follows: GI, on the one hand, and collectively Alnylam Pharma, Alnylam US
      and Alnylam Germany, on the other hand, shall each select, within 30
      (thirty) days after receipt of notice that arbitration is initiated, an
      independent and experienced third party as arbitrator. Such two selected
      arbitrators shall mutually select an independent and experienced third
      party as third arbitrator. The venue for such arbitration procedure shall
      be Munich, Germany, the language shall be English. The award of the
      arbitration shall be final and binding for the parties. Notwithstanding
      the foregoing, each party may apply for interlocutory relief in court.

9.    This Requirement Amendment may be executed in separate counterparts, each
      of which is deemed to be an original and all of which taken together
      constitute one and the same instrument.

In witness thereof the parties have caused this agreement to be executed by
their duly authorized representatives.

Garching Innovation GmbH

By: /s/ Dr. Bernhard Hertel
    -------------------------------------
Name: Dr. Bernhard Hertel
Title: Geschaftsfuhrer/Managing Director
Date: June 14, 2005

Requirement Amendment
Execution Copy

<PAGE>

                                     - 9 -

Alnylam Pharmaceuticals, Inc.

By: /s/ Barry Greene
    ----------------------------
Name: Barry Greene
Title: Chief Operating Officer
Date: June 7, 2005

Alnylam US, Inc.

By: /s/ Vincent J. Miles
    ----------------------------
Name: Vincent J. Miles
Title: Sr. Vice President Business Development
Date: June 7, 2005

Alnylam Europe AG

By: /s/ Roland Kreutzer
    ------------------------------
Name: Roland Kreutzer
Title: Managing Director
Date: June 13, 2005

Alnylam Europe AG

By: /s/ Andreas Bossko
    -----------------------
Name: Andreas Bossko
Title: Vice President, Finance
Date: June 13, 2005

Requirement Amendment
Execution CopyEx-10.11 Short-Term Incentive Plan

 

Exhibit 10.11

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions.

WRIGHT EXPRESS CORPORATION

SHORT-TERM INCENTIVE PLAN

ARTICLE 1- PURPOSE OF PLAN

Wright Express Corporation has adopted this Short-Term Incentive Plan to attract and retain
high-performing employees; to provide incentives for eligible employees to achieve specified
company, department and/or individual performance goals; and to reward such employees for the
achievement of specified goals on an annual basis. The Short-Term Incentive Plan is intended to
qualify as performance-based compensation under Section 162(m) of the Internal Revenue Code.

ARTICLE 2- DEFINITIONS

Wherever used in this document, the following terms have the meanings set forth below.

2.1 Appendix means an Appendix to this Plan document containing targets, payment metrics, and
other terms of the Plan (or modifications thereof) applicable to a specific Plan Year. The
Appendices shall be considered part of the Plan document.

2.2 Company means Wright Express Corporation.

2.3 Eligible Earnings means total gross pay for the applicable Plan Year (or the portion
thereof during which the Participant is actively employed), including, salary or wages classified
by the Company as regular; paid time off (PTO), whether planned or unplanned; holiday; bereavement;
jury duty; retroactive pay; and excluding, salary or wages classified by the Company as overtime,
shift differential, language differential, disability pay, commission/incentive pay, and bonuses.

2.4 Effective Date means January 1, 2005.

2.5 MBO means management by objectives.

2.6 Participant means an eligible employee who participates in the Plan for a Plan Year in
accordance with Article 3.

2.7 Plan means this Wright Express Corporation Short-Term Incentive Plan, as amended from time
to time, including the provisions of any Appendix, which are incorporated herein.

 

 

2.8 Plan Year means the fiscal year of the Company; as of the Effective Date, the Plan Year is
the calendar year.

ARTICLE 3- PARTICIPATION

3.1 Eligible Employees

Each full-time regular or part-time regular employee of the Company who meets the following
requirements shall be a Participant for a Plan Year:

     (a) The employee is not eligible for any other commission or incentive variable pay
plan of the Company.

     (b) The employee commences employment on or before November 1 of the applicable year;
and

     (c) Except as provided in Section 3.2, the employee is actively employed on the bonus
payment date for the applicable year.

3.2 Special Rules

     (a) A Participant who dies or becomes totally disabled during a Plan Year (as
determined under the Company’s Long-Term Disability program) may receive a pro-rated bonus
for the applicable year based on his or her Eligible Earnings during the period of the
Participant’s active employment. Any bonus payable to a deceased Participant shall be paid
to his or her personal representative.

     (b) A Participant who is not actively employed on the bonus payment date for a Plan
Year due to an approved leave of absence may receive a pro-rated bonus for the applicable
year based on his or her Eligible Earnings during the period of the Participant’s active
employment.

ARTICLE 4- ANNUAL INCENTIVES

The Corporate and Executive Officer MBOs for each Plan Year shall be approved by the Compensation
Committee of the Company’s Board of Directors, or its delegate.

An Individual Effectiveness Factor (“IEF”) shall be assigned to an employee classified as an
“associate” based on criteria established by the Company. The IEF for each associate shall be
initially established at 1.00. An associate’s IEF for a Plan Year may be adjusted down, but not
be-low 0.50, or up, but not above 1.50, in increments of 0.05, by action of his or her supervisor
with the approval of his or her division Senior Vice President and the Company’s President and
Chief Executive Officer. However, the foregoing adjustments (in the aggregate) must not increase
the total amount payable under the Plan for the given year.

The performance measures applicable to a Plan Year shall be set out in the Appendix.

 

 

ARTICLE 5- PAYMENTS

5.1 Time and Form

Bonuses shall be calculated and paid in a single payment for the applicable year, by no later than
March 31 of the following year.

5.2 Position Changes

“Position changes” for a Plan Year include promotions, demotions, and transfers between positions
and/or departments.

     (a) For a non-Management Participant, the amount of the Participant’s bonus is
calculated based on his or her position on December 31 of the applicable year.

     (b) For a Participant who is a Manager, Vice President, Senior Vice President, or the
President and Chief Executive Officer, the amount of the Participant’s bonus is calculated
based on pro-ration for each position change and each target percentage change during the
applicable year (excluding target percentage changes resulting from a market adjustment).

     (c) For a Participant who is an eligible employee for a portion of the year and an
ineligible employee for a portion of the year, the amount of the Participant’s bonus is
calculated based on pro-ration for the portion of the year in which he or she was an
eligible employee.

5.3 Taxes

All federal, state or local taxes that the Plan Administrator determines are required to be
withheld from any payments made under the Plan shall be withheld.

ARTICLE 6- ADMINISTRATION

6.1 Plan Administrator

The Plan shall be administered by the Compensation Committee of the Company’s Board of Directors,
which may delegate administrative responsibility in whole or in part to the President and Chief
Executive Officer and/or the Senior Vice President, Human Resources (“Administrators”), subject to
any requirements for review and approval that may be established by the Compensation Committee. In
all areas not specifically reserved for such review and approval, the decisions of the applicable
Administrator shall be binding on the Company and each eligible employee under Article 3.
Notwithstanding the foregoing, the Compensation Committee may not modify MBOs or other performance
criteria during a Plan Year so as to increase the payment to a Section 162(m) Participant (as
defined below) or exercise its discretion to increase the amount of incentive pay that would
otherwise be due a Section 162(m) Participant upon attainment of a performance goal.

 

 

6.2 Claims

Claims regarding payments under the Plan shall be directed to a Participant’s direct supervisor
and/or the Company’s Compensation Department. Any claim regarding the amount of any bonus payment
hereunder shall be made within 30 days of the date of such payment, or shall be forfeited.

ARTICLE 7- AMENDMENT AND TERMINATION

The Company reserves the right to terminate, amend, modify and/or restate this Plan, in whole or in
part, at will at any time, with or without advance notice.

ARTICLE 8- MISCELLANEOUS

8.1 Payment Adjustments and Special Circumstances

Subject to the approval of the Compensation Committee, the President and Chief Executive Officer
and the Senior Vice President, Human Resources, acting together, shall have the power to adjust
payments under the Plan (upward or downward) as and to the extent appropriate to achieve the stated
goals and purposes of the Plan and may approve exceptions to the Plan under special circumstances,
to avoid undue hardship with respect to a Participant. Notwithstanding the foregoing, the
President and CEO and the Senior Vice President, Human Resources may not increase or accelerate the
payment due to any Section 162(m) Participant with respect to any Plan Year. The term “Section
162(m) Participant” shall mean the President and CEO and each of the four highest paid officers of
the Company (other than the President and CEO) on the last day of the taxable year, for purposes of
the executive compensation disclosure rules under the Securities Exchange Act of 1934.

8.2 Information

The Plan Administrators shall be responsible for ensuring effective communication of the Plan to
eligible employees. Copies of the Plan shall be available to all Participants. All modifications
and changes to the Plan shall be appropriately documented and communicated to Participants.

8.3 No Guarantee of Payment

The Company does not guarantee payment of any bonus amounts hereunder, except to the extent that
payment is required by applicable law.

8.4 Limitation of Employees’ Rights

Nothing contained in the Plan shall confer upon any person a right to be employed or to continue in
the employ of the Employer, or interfere in any way with the right of the Employer to terminate the
employment of a Participant at any time, with or without cause.

 

 

IN WITNESS WHEREOF, Wright Express Corporation has caused this document to be executed by its duly
authorized officer this 17th day of May, 2005.

	 	 	 	 	 
	WRIGHT EXPRESS CORPORATION	 	 
	 
	 	 	 	 
	 

	 	/s/ Robert C. Cornett	 	 
	 

	 	 	 	 
	By:

	 	Robert C. Cornett	 	 
	Its:

	 	Senior Vice President, Human Resources	 	 
	Date:

	 	May 17, 2005	 	 
	 

	 	 	 	 

 

 

APPENDIX I

2005 STIP FACTORS

STIP Weightings

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	WEX Corporate MBOs	 	 	 	 	 	 	 
	 	 	PPG1 Adj	 	 	 	 	 	 	 
	 	 	Net	 	 	PPG1 Adj	 	 	Exec Shared, VP &	 
	 	 	Income2	 	 	Revenue	 	 	Dept MBOs	 
	President / CEO
	 	 	70%	 	 	 	30%	 	 	 	  0%	 
	Executive Team3
	 	 	60%	 	 	 	20%	 	 	 	20%	 
	Vice Presidents
	 	 	50%	 	 	 	15%	 	 	 	35%	 
	Managers
	 	 	40%	 	 	 	10%	 	 	 	50%	 
	Individual Contributors
	 	 	40%	 	 	 	10%	 	 	 	50%	 

 

			
	1	 	PPG — price per gallon
	 
	2	 	PPG Adjusted Net Income excluding any unrealized gain/loss from the hedge or Q1
non-recurring charges.
	 
	3	 	 The following weightings apply only to the SVP Sales:

          50% — Executive Team MBOs

          50% — Sales MBOs

Payout Levels

	 	 	 	 	 
	Performance Results	 	Payout %	 
	Threshold
	 	 	50	%
	Target
	 	 	100	%
	Max
	 	 	150	%

 

 

MBOs

Corporate MBOs

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Performance Goal	 	Threshold Performance	 	Target Performance	 	 	Maximum Performance	 
	PPG1 Adj Net Income2

	 	$	 	[**]
	 	$	[**]
	 	 	$	 	[**]	 
	PPG1 Adj Revenue

	 	$	 	[**]
	 	$	[**]
	 	 	$	 	[**]	 

 

			
	1	 	PPG — price per gallon

	 
	2	 	PPG Adjusted Net Income excluding any unrealized gain/loss from the hedge or Q1
non-recurring charges.

In 2005, the Company must achieve at least threshold results for PPG Adjusted Net Income in
order to pay out any portion of the Short-Term Incentive Plan.

Executive
Officer MBOs

All
Senior Vice Presidents share the following MBOs:

	 	 	 	 	 	 	 
	Performance Goal	 	Threshold Performance	 	Target Performance	 	Maximum Performance
	New Product Revenue

	 	$ [**]
	 	$ [**]
	 	$ [**]
	Strategic

Initiatives

	 	[**] from the list

below
	 	[**] from the list below
	 	[**] from the list below

New Product Revenue primarily includes the following new products:

[**]                [**]

[**]                [**]

[**]                [**]

[**]

Strategic Initiatives include:

[**]

[**]

[**]

[**]

[**]

[**]

[**]

[**]

Vice
President MBOs

Each Vice President generally has [**] MBOs. While the MBOs are specific to the individual Vice
President most Vice Presidents will have one cross-functional MBO shared with another Vice
President.

Department
MBOs

Each Manager generally has [**] MBOs shared by all STIP-eligible members of their department.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}]]